

## SUPPLEMENTARY INFORMATION

### **Integrative Genomics of Gene and Metabolic Regulation by Estrogen Receptors $\alpha$ and $\beta$ and Coregulators**

Zeynep Madak-Erdogan, Tze-Howe Charn, Yan Jiang, Edison T. Liu, John A. Katzenellenbogen, and Benita S. Katzenellenbogen

#### **Contents**

Supplementary Figures 1-10 Legends

Supplementary Tables 1-3 Titles

**Supplementary Figure Legends and Table Titles**

**Supplementary Figure 1.** Western blot showing presence of ER $\alpha$  and/or ER $\beta$  in ER $\alpha$ , ER $\alpha$ /ER $\beta$ , and ER $\beta$  MCF-7 cells. Cells treated with control vehicle (V) or 10 nM estradiol (E2) for 24 h before cell harvest and preparation of cell extracts. Equal amounts of protein were loaded per lane.  $\beta$ -actin is the internal loading reference.

**Supplementary Figure 2.** Categorization of binding sites into clusters based on colocalization of ER $\alpha$ , ER $\beta$ , RIP140, and SRC3, from our findings, and FOXA1 and GATA3, from data in Joseph et al, 2010 and Kong et al, 2011.

**Supplementary Figure 3.** RIP140 recruitment to various binding sites.

**Supplementary Figure 4.** RIP140 is required for E2 mediated cell proliferation in MCF-7 cells. **A.** Cell proliferation, **B.** FACS analysis and **C.** Gene expression analysis for G2/M associated genes in the three different cell backgrounds (ER $\alpha$ , ER $\alpha$ /ER $\beta$  and ER $\beta$  cells), which were wild type (siCtrl cells) or RIP140 depleted using shRNA (siRIP140 cells).

**Supplementary Figure 5.** Hierarchical clustering of gene expression values for G2/M activators and G2/M inhibitors in the three different cell backgrounds.

**Supplementary Figure 6.** Binding sites for ER $\alpha$ , ER $\beta$ , RIP140 and SRC3 for adipogenesis-associated genes studied in Figure 6.

**Supplementary Figure 7.** Impact of SRC3 or RIP140 knockdown on gene expression or recruitment of each coregulator to binding sites for adipogenesis genes DDIT3 and FOXO1A or pS2 and OTUB2.

**Supplementary Figure 8.** Impact of ER $\beta$  on **A.** Cell proliferation, **B.** Adipogenesis and **C.** Gene expression in T47D cells.

**Supplementary Figure 9.** Association of the ER $\beta$  and RIP140 gene signature with various concepts in tumor datasets.


**Supplementary Figure 10.** Association of the ER $\beta$  and RIP140 gene signature with clinical outcome in various breast cancer data sets. Using Oncomine concept maps, the ER $\beta$ /RIP140 gene signature was found to be significantly associated with outcome - metastasis, survival and recurrence- (yellow circles) in several data sets (red circles). Cytoscape software was used to generate the association map. Association P values were denoted on the edges for each data set and concept.

**Supplementary Table 1.** CEAS analysis of transcription factor binding motif enrichment for binding site clusters (C1-C11) identified through SeqMINER analysis.


**Supplementary Table 2.** SeqPos analysis of transcription factor binding motif enrichment for binding site clusters identified through SeqMINER analysis

**Supplementary Table 3.** Functional enrichment of categories for ER $\beta$ -modulated genes. Enrichment by Pathway Maps; Enrichment by Process Networks; and Enrichment by Molecular Networks are shown.













**Supplementary Figure 1**




Supplementary Figure 2


**A****B****Supplementary Figure 3**

**A****Cell Proliferation****B****siCtrl Cells-FACS Analysis****siRIP140-FACS Analysis****C****Ki-67****FOXM1****BIRC5****Supplementary Figure 4**

### G2/M Activators




### G2/M Inhibitors




Supplementary Figure 5


0.25  
0.40  
0.62  
0.00  
1.59  
2.51  
4.00



## Supplementary Figure 6



Supplementary Figure 7



**Supplementary Figure 8**



## Associated Concept Summary for "NRIP1sig - My Concepts"

Threshold (Odds Ratio): 2.0  
Oncomine Concept Summary

Threshold (P-value): 1E-4

Data Type: All

Concept Type by Cancer	Cancer vs. Normal	Cancer Subtype Analysis											Cancer vs. Baseline (DNA only)	Pathway and Drug	Single Cancer Oncomine Clusters							
		Cancer vs. Cancer	Multi-cancer	Clinical Outcome	Metastasis vs. Primary	Molecular Subtype: Biomarker	Molecular Subtype: Mutation	Pathology Subtype: Grade	Pathology Subtype: Stage	Patient Treatment Response	Recurrence vs. Primary	Other										
Bladder Cancer															3							
Brain and CNS Cancer	1	1													3							
Breast Cancer	8	3		23		36	13		4	10	4	1			5							
Cervical Cancer															3							
Colorectal Cancer	1	1		1											1							
Esophageal Cancer		1													3							
Gastric Cancer		1													1							
Head and Neck Cancer		1													3							
Kidney Cancer			1												1							
Leukemia								1	2					2								
Liver Cancer				1				1							3							
Lung Cancer		1	1		1			1		1				2	3							
Lymphoma	1	1													1							
Melanoma	1			1			1	1						1	1							
Myeloma							1								1							
Other Cancer	2	1					1					1			2							
Ovarian Cancer		5					1								2							
Pancreatic Cancer														1	1							
Prostate Cancer	1		1		1					2					1							
Sarcoma				1	1		1							1	1							
Significant Unique Concepts	2	9	12	7	2	1	3	25	1	36	13	2	7	12	7	1	1	5	1	1	4	32

Red: Over-expression    Blue: Under-expression

### Other (Non-Oncomine) Concept Summary


Biological Annotations	Pathway Concepts	Regulatory Concepts	Connectivity Map v2 Drug Signatures	Literature-defined Concepts	Mutation Concepts	My Concepts	shRNA Concepts
		1	12	6		1	

Copyright© 2008-11 Compendia Bioscience, Inc. Images from Oncomine™ may be used in publications with proper citation. The citation for Oncomine is as follows: Oncomine™ (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization. For further information, refer to the terms described in the license agreement.

Oncomine Source:

[https://www.oncomine.com/resource/main.html#cc:122202926,19866,31124,122202938,28380,122196695,28428,28404,28459;cso:pvalue;cv:association;dso:geneUnderex;ec:\[2,5\];epv:108715,3508;et:under;pg:1;pvf:C30743;scr:conceptSummary;v:16](https://www.oncomine.com/resource/main.html#cc:122202926,19866,31124,122202938,28380,122196695,28428,28404,28459;cso:pvalue;cv:association;dso:geneUnderex;ec:[2,5];epv:108715,3508;et:under;pg:1;pvf:C30743;scr:conceptSummary;v:16)

## Supplementary Figure 9



Supplementary Figure 10